MX364689B - Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. - Google Patents
Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer.Info
- Publication number
- MX364689B MX364689B MX2015013235A MX2015013235A MX364689B MX 364689 B MX364689 B MX 364689B MX 2015013235 A MX2015013235 A MX 2015013235A MX 2015013235 A MX2015013235 A MX 2015013235A MX 364689 B MX364689 B MX 364689B
- Authority
- MX
- Mexico
- Prior art keywords
- peptide
- immunogen constructs
- alzheimer
- peptide immunogen
- immunotherapy
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 238000009169 immunotherapy Methods 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 7
- 230000002163 immunogen Effects 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- General Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/843,883 US9102752B2 (en) | 2013-03-15 | 2013-03-15 | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| PCT/US2013/037865 WO2014143087A1 (en) | 2013-03-15 | 2013-04-23 | Peptide vaccine for prevention and immunotherapy of dementia of the alzheimer's type |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015013235A MX2015013235A (es) | 2016-04-04 |
| MX364689B true MX364689B (es) | 2019-05-06 |
Family
ID=51527985
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015013235A MX364689B (es) | 2013-03-15 | 2013-04-23 | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. |
| MX2019005268A MX2019005268A (es) | 2013-03-15 | 2015-09-15 | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019005268A MX2019005268A (es) | 2013-03-15 | 2015-09-15 | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9102752B2 (OSRAM) |
| EP (1) | EP2968485B1 (OSRAM) |
| JP (3) | JP6208319B2 (OSRAM) |
| KR (2) | KR20180132962A (OSRAM) |
| CN (2) | CN108794615A (OSRAM) |
| AU (3) | AU2013381835A1 (OSRAM) |
| BR (1) | BR112015023105A8 (OSRAM) |
| CA (1) | CA2906313A1 (OSRAM) |
| DK (1) | DK2968485T3 (OSRAM) |
| ES (1) | ES2800028T3 (OSRAM) |
| IL (2) | IL241597B (OSRAM) |
| MX (2) | MX364689B (OSRAM) |
| PT (1) | PT2968485T (OSRAM) |
| RU (1) | RU2696566C2 (OSRAM) |
| SG (1) | SG11201507669YA (OSRAM) |
| TW (1) | TWI561529B (OSRAM) |
| WO (1) | WO2014143087A1 (OSRAM) |
| ZA (2) | ZA201507526B (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
| AU2015243990A1 (en) * | 2014-04-07 | 2016-11-10 | La Jolla Pharmaceutical Company | Hepcidin mimetic peptides and uses thereof |
| WO2017131468A1 (ko) * | 2016-01-27 | 2017-08-03 | 경상대학교산학협력단 | 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물 |
| EP3444344A4 (en) * | 2016-04-14 | 2020-02-19 | TAO Health Life Pharma Co., Ltd. | AMYLOSPHEROID TYPE STRUCTURE (ASPD) AND PHARMACEUTICAL COMPOSITION |
| CN106565847B (zh) * | 2016-10-26 | 2020-12-01 | 清华大学 | 化合物、多肽及其用途 |
| BR112019026707A2 (pt) * | 2017-06-16 | 2020-06-30 | United Neuroscience | imunógenos de peptídeo da extremidade c-terminal da proteína alfa-sinucleína e formulações dos mesmos para o tratamento de sinucleinopatias |
| JP2021508673A (ja) | 2017-10-27 | 2021-03-11 | ユナイテッド ニューロサイエンスＵｎｉｔｅｄ Ｎｅｕｒｏｓｃｉｅｎｃｅ | タウペプチド免疫原構築物 |
| CA3085318A1 (en) * | 2017-12-11 | 2019-06-20 | Ubi Ip Holdings | Peptide immunogens of il-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis |
| CA3087036A1 (en) * | 2017-12-31 | 2019-07-04 | United Biomedical, Inc. | Peptide immunogens and formulations thereof targeting membrane-bound ige for treatment of ige mediated allergic diseases |
| EP3752523A4 (en) * | 2018-02-13 | 2021-11-17 | Cedars-Sinai Medical Center | METHODS AND SYSTEMS FOR THE IDENTIFICATION AND TREATMENT OF PATHOLOGICAL NEURODEGENERENCE AND AGE-RELATED COGNITIVE DECLINE |
| WO2019197414A1 (en) | 2018-04-10 | 2019-10-17 | Ac Immune Sa | Anti-abeta therapeutic vaccines |
| MX2020011733A (es) * | 2018-05-04 | 2021-01-15 | Ubi Ip Holdings | Epítopos de células t cooperadoras promiscuos artificiales que facilitan la producción de anticuerpos diana con respuesta inflamatoria de células t limitada. |
| TWI676635B (zh) * | 2018-06-15 | 2019-11-11 | 英屬開曼群島商聯腦科學公司 | α－突觸核蛋白Ｃ端胜肽免疫原及其用於治療突觸核蛋白疾病的配方 |
| WO2020072428A1 (en) * | 2018-10-01 | 2020-04-09 | United Neuroscience | Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72 |
| MX2021007446A (es) * | 2018-12-19 | 2021-09-08 | United Biomedical Inc | Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos. |
| MX2021007906A (es) * | 2018-12-28 | 2021-10-13 | United Biomedical Inc | Nmunógenos peptídicos dirigidos a la interleucina 6 (il-6) y sus formulaciones para la inmunoterapia de enfermedades afectadas por la desregulación de la il-6. |
| EP3906316A4 (en) * | 2018-12-31 | 2022-11-30 | United Neuroscience Limited | PEPTIDE IMMUNOGENS FOR TARGETING CALCITONINGEN-RELATED PEPTIDE (CGRP) AND FORMULATIONS THEREOF FOR THE PREVENTION AND TREATMENT OF MIGRAINE |
| CN110759987B (zh) * | 2019-10-29 | 2021-06-08 | 中国人民解放军军事科学院军事医学研究院 | 构象特异性的重组Aβ1-42样寡聚体抗原、其制备方法和应用 |
| WO2021150910A1 (en) * | 2020-01-23 | 2021-07-29 | Ubi Ip Holdings | Peptide immunogens targeting pituitary adenylate cyclase-activating peptide (pacap) and formulations thereof for prevention and treatment of migraine |
| MX2022011199A (es) | 2020-03-10 | 2022-12-07 | Lifearc | Peptidos ciclicos. |
| CA3195783A1 (en) | 2020-11-17 | 2022-05-27 | Keith Rubin | Treatment and prevention of neuropathology associated with neurodegenerative diseases |
| EP4307988A4 (en) * | 2021-03-16 | 2025-01-22 | NeuroVision Imaging, Inc. | BIOFLUID-BASED METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH ALZHEIMER'S DISEASE |
| JP2024534269A (ja) * | 2021-08-30 | 2024-09-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 神経変性疾患を治療するための方法および物質 |
| WO2023106319A1 (ja) | 2021-12-08 | 2023-06-15 | 国立大学法人大阪大学 | 抗ｉｌ－２３抗体誘導用ワクチン組成物 |
| AU2023223603A1 (en) | 2022-02-28 | 2024-08-22 | Tridem Bioscience Gmbh & Co Kg | A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN. |
| KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
| CN115417915B (zh) * | 2022-11-03 | 2023-02-24 | 北京引正基因科技有限公司 | 多肽载体及其应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
| WO2025109524A1 (en) | 2023-11-22 | 2025-05-30 | Ac Immune Sa | Assays and methods for assessing vaccine preparations |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5753624A (en) | 1990-04-27 | 1998-05-19 | Milkhaus Laboratory, Inc. | Materials and methods for treatment of plaquing disease |
| CA2081482C (en) | 1990-04-27 | 2000-11-21 | Ellis L. Kline | Method and composition for treatment of central nervous system disease states associated with abnormal amyloid beta protein molecular organization |
| US5955317A (en) | 1993-01-25 | 1999-09-21 | Takeda Chemical Industries, Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| AU7043894A (en) | 1993-05-28 | 1994-12-20 | Miriam Hospital, The | Composition and method for (in vivo) imaging of amyloid deposits |
| EP0725838A4 (en) | 1993-10-26 | 1997-02-26 | United Biomedical Inc | STRUCTURED SYNTHETIC ANTIGAN BANKS AS DIAGNOSTICS, VACCINE AND THERAPEUTIC AGENTS |
| US6787523B1 (en) | 1997-12-02 | 2004-09-07 | Neuralab Limited | Prevention and treatment of amyloidogenic disease |
| US6750324B1 (en) | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6025468A (en) | 1998-06-20 | 2000-02-15 | United Biomedical, Inc. | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic LHRH peptides |
| TWI229679B (en) | 1998-06-20 | 2005-03-21 | United Biomedical Inc | Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens |
| CA2349434A1 (en) | 1999-09-03 | 2001-03-15 | Ramot University Authority For Applied Research & Industrial Development Ltd. | Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases |
| IL149976A0 (en) | 1999-12-08 | 2002-12-01 | Mindset Biopharmaceuticals Usa | Chimeric peptides as immunogens, antibodies thereto, and methods for immunization using chimeric peptides or antibodies |
| US20030165481A1 (en) | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| US20030083277A1 (en) * | 2000-02-24 | 2003-05-01 | Hersh Louis B. | Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients |
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
| US8088388B2 (en) | 2002-02-14 | 2012-01-03 | United Biomedical, Inc. | Stabilized synthetic immunogen delivery system |
| CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| JP2007522119A (ja) * | 2004-01-28 | 2007-08-09 | キュリックス エーピーエス | アミロイド関連疾患用ワクチンとしてのアミロイドタンパク質のコンジュゲート |
| JP5097695B2 (ja) * | 2006-02-22 | 2012-12-12 | 株式会社林原 | 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン |
| CN101384279B (zh) * | 2006-02-24 | 2012-02-22 | 奇斯药制品公司 | 抗淀粉样蛋白免疫原性组合物、方法和用途 |
| US20090123488A1 (en) * | 2006-08-14 | 2009-05-14 | Thymon, Llc | Compositions and methods for the treatment and prophylaxis of Alzheimer's disease |
| AT506820B1 (de) | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| CA2736729A1 (en) * | 2008-09-29 | 2010-04-01 | Ben Gurion University Of The Negev Research And Development Authority | Amyloid beta-peptides and methods of use thereof |
| US9067981B1 (en) * | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
| WO2012056008A1 (en) * | 2010-10-28 | 2012-05-03 | Jonas Nilsson | Diagnosis and treatment of alzheimer's disease |
| US9102752B2 (en) * | 2013-03-15 | 2015-08-11 | United Biomedical, Inc. | Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type |
-
2013
- 2013-03-15 US US13/843,883 patent/US9102752B2/en active Active
- 2013-04-23 KR KR1020187034866A patent/KR20180132962A/ko not_active Ceased
- 2013-04-23 KR KR1020157029184A patent/KR101926030B1/ko active Active
- 2013-04-23 WO PCT/US2013/037865 patent/WO2014143087A1/en not_active Ceased
- 2013-04-23 PT PT138780929T patent/PT2968485T/pt unknown
- 2013-04-23 CA CA2906313A patent/CA2906313A1/en not_active Abandoned
- 2013-04-23 BR BR112015023105A patent/BR112015023105A8/pt not_active Application Discontinuation
- 2013-04-23 MX MX2015013235A patent/MX364689B/es active IP Right Grant
- 2013-04-23 AU AU2013381835A patent/AU2013381835A1/en not_active Abandoned
- 2013-04-23 JP JP2016500078A patent/JP6208319B2/ja active Active
- 2013-04-23 CN CN201810667175.6A patent/CN108794615A/zh active Pending
- 2013-04-23 EP EP13878092.9A patent/EP2968485B1/en active Active
- 2013-04-23 ES ES13878092T patent/ES2800028T3/es active Active
- 2013-04-23 DK DK13878092.9T patent/DK2968485T3/da active
- 2013-04-23 RU RU2015142996A patent/RU2696566C2/ru active IP Right Revival
- 2013-04-23 SG SG11201507669YA patent/SG11201507669YA/en unknown
- 2013-04-23 CN CN201380076473.3A patent/CN105228644B/zh active Active
-
2014
- 2014-03-14 TW TW103109373A patent/TWI561529B/zh active
-
2015
- 2015-08-11 US US14/824,075 patent/US20160068581A1/en not_active Abandoned
- 2015-09-15 MX MX2019005268A patent/MX2019005268A/es unknown
- 2015-09-16 IL IL241597A patent/IL241597B/en active IP Right Grant
- 2015-10-09 ZA ZA2015/07526A patent/ZA201507526B/en unknown
-
2017
- 2017-05-22 AU AU2017203425A patent/AU2017203425B2/en not_active Ceased
- 2017-06-07 JP JP2017112424A patent/JP6784646B2/ja active Active
-
2018
- 2018-04-19 US US15/957,798 patent/US20180244739A1/en not_active Abandoned
- 2018-12-31 US US16/237,531 patent/US20190194280A1/en not_active Abandoned
-
2019
- 2019-04-08 IL IL265910A patent/IL265910A/en unknown
- 2019-07-26 JP JP2019137534A patent/JP2019196397A/ja active Pending
- 2019-10-10 ZA ZA2019/06683A patent/ZA201906683B/en unknown
- 2019-10-11 AU AU2019246916A patent/AU2019246916A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015013235A (es) | Vacuna peptidica para prevencion e inmunoterapia de la demencia tipo alzheimer. | |
| SG10201903538YA (en) | Modified virus-like particles of cmv | |
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| DOP2013000235A (es) | Proteínas de fusión y vacunas de combinación que comprenden proteína e y pilina a de haemophilus influenzae. | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| CY1120430T1 (el) | Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων | |
| EA201290675A1 (ru) | Вакцинные векторы и способы усиления иммунных ответов | |
| EA201590427A1 (ru) | Нелинейные сахаридные конъюгаты | |
| EA202090319A1 (ru) | Пептидные конъюгаты, способ конъюгации и их использование | |
| MX363149B (es) | Vacunas de nucleoproteina de la influenza. | |
| FI20115374A0 (fi) | Uudet hypoallergeenit | |
| PH12014501795B1 (en) | Rotavirus subunit vaccines and methods of making and use thereof | |
| NZ704188A (en) | Attenuated swine influenza vaccines and methods of making and use thereof | |
| MX2019007924A (es) | Vacunas contra la influenza. | |
| IN2014DN09445A (OSRAM) | ||
| WO2018066999A3 (en) | Chimeric enterovirus virus-like particles | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| IN2015DN03925A (OSRAM) | ||
| AR093530A1 (es) | Adyuvante de vacunacion, preparacion, y vacunas que lo contienen | |
| WO2015070207A3 (en) | Ama-1 epitopes, antibodies, compositions, and methods of making and using the same | |
| WO2010080188A3 (en) | Epitope targeted anthrax vaccine | |
| SG10201900933YA (en) | Koc1-derived peptide and vaccine including same | |
| MX374919B (es) | ANTÍGENOS Y COMBINACIONES DE ANTÍGENOS PARA USARSE PARA ELEVAR LA RESPUESTA INMUNE CONTRA Haemophilus influenzae. | |
| SG10201900835XA (en) | Urlc10-derived peptide and vaccine containing same | |
| WO2014152271A8 (en) | Viral proteins as immunomodulatory agents and vaccine components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |